Published in Am J Hypertens on July 01, 1993
Alteration of podocyte protein expression and localization in the early stage of various hemodynamic conditions. Int J Mol Sci (2013) 0.79
Salt-Sensitive Hypertension: Perspectives on Intrarenal Mechanisms. Curr Hypertens Rev (2015) 0.77
Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: A PRISMA-compliant meta-analysis. Medicine (Baltimore) (2016) 0.75
Relationship between diurnal blood pressure and renal histopathological changes in white coat hypertension. J Nephrol (2017) 0.75
Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med (1999) 4.82
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (2004) 2.07
Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int (2007) 1.83
Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest (2003) 1.49
Diabetic nephropathy in type II diabetes. Am J Kidney Dis (1996) 1.44
Right-sided chest pain at the onset of haemodialysis. Nephrol Dial Transplant (2001) 1.44
Use of hydro-jet cutting for laparoscopic partial nephrectomy in a porcine model. Urology (2001) 1.39
Type II diabetes mellitus: is the renal risk adequately appreciated? Nephrol Dial Transplant (1991) 1.39
Nephropathy in type 2 diabetes. J Intern Med (1999) 1.21
Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets (2005) 1.11
Renal function in the elderly--is the dogma of an inexorable decline of renal function correct? Nephrol Dial Transplant (1997) 1.04
Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int (1994) 1.03
Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res (2010) 0.97
Renal findings in patients with short-term type 2 diabetes. J Am Soc Nephrol (1996) 0.96
One for all--a multi-use dialysis system for effective treatment of severe thallium intoxication. Kidney Blood Press Res (2004) 0.96
Efficiency of high-flux hemodialysis in the treatment of valproic acid intoxication. J Toxicol Clin Toxicol (2003) 0.93
High-flux hemodialysis--an effective alternative to hemoperfusion in the treatment of carbamazepine intoxication. Clin Nephrol (2002) 0.93
Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners. J Hypertens (1996) 0.92
Erythropoietin and progression of CKD. Kidney Int Suppl (2007) 0.91
Insulin action and non-esterified fatty acids. The European Group for the Study of Insulin Resistance (EGIR). Proc Nutr Soc (1997) 0.90
Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. Int J Clin Pract (2010) 0.90
Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. Clin Nephrol (2004) 0.88
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. Eur J Med Res (2008) 0.88
Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis (1993) 0.87
[Fulminant course of leptospirosis complicated by multiple organ failure]. Z Gastroenterol (2001) 0.86
Vascular endothelial damage and repair in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2007) 0.85
Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res (2004) 0.85
Loop diuretics and thiazides--the case for their combination in chronic renal failure. Nephrol Dial Transplant (1996) 0.84
ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol Dial Transplant (2001) 0.84
BK polyomavirus-specific cellular immune responses are age-dependent and strongly correlate with phases of virus replication. Am J Transplant (2014) 0.84
Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma. Int Immunol (1997) 0.82
Changes in plasma phosphate levels influence insulin sensitivity under euglycemic conditions. J Clin Endocrinol Metab (1996) 0.82
The sympathetic nervous system and the kidney: its importance in renal diseases. Blood Press Suppl (1998) 0.81
Predictive factors for urinary retention following kidney transplantation in male patients. Scand J Urol Nephrol (2011) 0.81
What is the appropriate dialysate calcium concentration for the dialysis patient? Nephrol Dial Transplant (1996) 0.81
CD80-transfected human breast and ovarian tumor cell lines: improved immunogenicity and induction of cytolytic CD8+ T lymphocytes. Cytokines Mol Ther (1995) 0.80
The history of salt - aspects of interest to the nephrologist. Nephrol Dial Transplant (1996) 0.80
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol (2002) 0.80
Clinical nephrology in 19th century Germany. Am J Nephrol (1994) 0.80
Osteodystrophy in the millennium. Kidney Int Suppl (1999) 0.79
The effect of malnutrition on cardiovascular mortality in dialysis patients: is L-arginine the answer? Nephrol Dial Transplant (1994) 0.79
The kidney in congestive heart failure. Eur Heart J (1991) 0.79
Proteinuria and hypertension. Kidney Int Suppl (1994) 0.78
Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells. J Mol Med (Berl) (1996) 0.78
Ambulatory blood pressure monitoring: fancy gadgetry or clinically useful exercise? Nephrol Dial Transplant (2001) 0.78
Erythropoiesis-stimulating agents: past and future. Kidney Int Suppl (2007) 0.78
Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. J Urol (2001) 0.78
Biocompatibility parameters of different dialysis membranes assessed during systemic inflammation. Blood Purif (2005) 0.78
Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens Suppl (1997) 0.78
A hibernating kidney - ischemic preconditioning in a renal transplant recipient with a proximal stenosis of the iliac artery. Clin Nephrol (2008) 0.78
Chronic erythropoietin treatment affects different molecular pathways of diabetic cardiomyopathy in mouse. Eur J Clin Invest (2009) 0.77
Early epoetin treatment in patients with renal insufficiency. Nephrol Dial Transplant (2000) 0.77
Provocation of pulmonary haemorrhage in Goodpasture syndrome by chlorine gas. Nephrol Dial Transplant (1993) 0.77
Frequency and clinical influence of lymphoceles after kidney transplantation. Transplant Proc (1990) 0.77
[Active surveillance for renal cell carcinoma]. Aktuelle Urol (2012) 0.77
Hypertension and the kidney--an overview. Am J Kidney Dis (1993) 0.76
The role of the parathyroid glands in the uremic syndrome. Am J Kidney Dis (1995) 0.76
Counteracting progression of renal disease: A look into the future. Kidney Int Suppl (2000) 0.76
Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment. Eur J Clin Pharmacol (1994) 0.76
Clinical problem-solving: stopping short of certainty. N Engl J Med (1994) 0.75
[Complete remission of pulmonary metastasis from renal cell carcinoma through inhalation therapy with Interleukin-2 after unsuccessful systemic immunochemotherapy]. Urologe A (2004) 0.75
[Inhibition of the progression of renal failure in glomerular diseases]. Internist (Berl) (1993) 0.75
[Autoantibodies in kidney diseases]. Z Arztl Fortbild (Jena) (1994) 0.75
Prescription of calcium concentration and PTH control. Perit Dial Int (1996) 0.75
Are newer antihypertensive agents really more effective than traditional drugs in progressive renal disease? Am J Kidney Dis (1991) 0.75
Treatment with high doses of loop diuretics in chronic renal failure. Nephrol Dial Transplant (1994) 0.75
How can we improve prognosis in diabetic patients with end-stage renal disease? Diabetes Care (1999) 0.75
Does occupational exposure to toxins increase albumin excretion rate? Kidney Int (1998) 0.75
Clinical relevance of albuminuria in hypertensive patients. Clin Investig (1992) 0.75
[Acute renal failure. Extracorporeal therapy]. Internist (Berl) (2007) 0.75
[Dyslipoproteinemia: its importance in nephrology]. Z Kardiol (1993) 0.75
Renal involvement in type II diabetes. Curr Opin Nephrol Hypertens (1994) 0.75
Ex-vivo comparison of the haemostatic properties of standard transurethral resection and transurethral vaporization resection of the prostate. BJU Int (2003) 0.75
[Regeneration of renal tissue -- therapy of the future?]. Dtsch Med Wochenschr (2006) 0.75
OACE inhibition does not interfere with acute extrarenal or renal potassium disposal in chronic renal failure. Eur J Clin Pharmacol (1994) 0.75
[Nephroprotection with ACE inhibitors]. Verh Dtsch Ges Inn Med (1991) 0.75
[The metabolic syndrome]. Dtsch Med Wochenschr (1995) 0.75
Optimizing antihypertensive therapy in patients with diabetic nephropathy. J Hypertens Suppl (1998) 0.75
Hormonal disturbances of calcium metabolism in renal failure. Curr Opin Nephrol Hypertens (1993) 0.75
[DGFIT: Immune and Targeted Therapy at ASCO 2016 - What will the Future Bring?] Aktuelle Urol (2016) 0.75
Albuminuria of hypertensive patients. Clin Nephrol (1992) 0.75
Renal involvement in type II diabetes. Adv Nephrol Necker Hosp (1995) 0.75
Effects of angiotensin-converting enzyme inhibition on renal sodium handling after furosemide injection. Clin Investig (1993) 0.75
[Current therapy of chronic kidney insufficiency]. Urologe A (1991) 0.75
Pathophysiology and treatment of hypertension and oedema due to renal failure. Cardiology (1994) 0.75
[DGFIT: Immune and targeted therapy in urologic oncology – what can be expected?]. Aktuelle Urol (2012) 0.75
How many patients with renal insufficiency survive until end-stage renal failure? Nephrol Dial Transplant (1991) 0.75
The optimal target hemoglobin. Semin Nephrol (2000) 0.75
Effect of moxonidine on urinary electrolyte excretion and renal haemodynamics in man. Eur J Clin Pharmacol (1995) 0.75
Inhibition of complement activation with EDTA in vivo during sham hemodialysis. Int J Artif Organs (1991) 0.75